| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H17N5O2 |
| Molar mass | 335.367 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Panadiplon (U-78875) is ananxiolytic drug with a novelchemical structure that is not closely related to other drugs of this type. It has a similar pharmacological profile to thebenzodiazepine family of drugs, but with mainly anxiolytic properties and relatively littlesedative oramnestic effect, and so is classified as anonbenzodiazepine anxiolytic.[1]
Panadiplon acts as a high-affinityGABAA receptorpartial agonist,[2][3] but despite showing a useful effects profile of a potent anxiolytic with little sedative effects, panadiplon was discontinued from clinical development for use in humans after showing evidence of liver damage in both animals and human trials.[4][5] Panadiplon however continues to be used in animal research, mainly as a subtype-selective reference drug to compare other GABAA agonists against.[6][7]